Cargando…
HDAC inhibitors enhance the immunotherapy response of melanoma cells
We focused on the ability of the pan-histone deacetylase (HDAC) inhibitors AR42 and sodium valproate to alter the immunogenicity of melanoma cells. Treatment of melanoma cells with HDAC inhibitors rapidly reduced the expression of multiple HDAC proteins as well as the levels of PD-L1, PD-L2 and ODC,...
Autores principales: | Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Dent, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669957/ https://www.ncbi.nlm.nih.gov/pubmed/29137331 http://dx.doi.org/10.18632/oncotarget.17950 |
Ejemplares similares
-
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017) -
The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019) -
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021) -
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2017) -
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)